☰

Csaba Farsang - Publications

Affiliations: 
Semmelweis Egyetem, Hungary 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Dézsi CA, Glezer M, Karpov Y, Brzozowska-Villatte R, Farsang C. Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies. Advances in Therapy. PMID 33150570 DOI: 10.1007/s12325-020-01527-3  0.311
2018 Járai Z, Kolossváry E, Szabó I, Kiss I, Farsang C, Farkas K. [The potential role of oscillometric devices for ankle-brachial index measurements in clinical practice]. Orvosi Hetilap. 159: 176-182. PMID 29376424 DOI: 10.1556/650.2018.30957  0.509
2015 Denardo SJ, Gong Y, Cooper-DeHoff RM, Farsang C, Keltai M, Szirmai L, Messerli FH, Bavry AA, Handberg EM, Mancia G, Pepine CJ. Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy. Plos One. 10: e0122726. PMID 25835002 DOI: 10.1371/journal.pone.0122726  0.338
2014 Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, Silani V, Bilo G, Corrao G, Zambon A, Scotti L, Zhang X, Wang H, Zhang Y, Zhang X, ... ... Farsang C, et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. Journal of Hypertension. 32: 1888-97. PMID 24979303 DOI: 10.1097/Hjh.0000000000000254  0.316
2013 Farsang C. Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice. Blood Pressure. 22: 3-10. PMID 23163322 DOI: 10.3109/08037051.2012.740787  0.368
2012 Gupta M, Martineau P, Tran T, Després JP, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Blanco-Colio LM, Egido J, Langer A. Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Journal of Clinical Pharmacology. 52: 850-8. PMID 21610204 DOI: 10.1177/0091270011407196  0.323
2011 Grassi G, Cifkova R, Laurent S, Narkiewicz K, Redon J, Farsang C, Viigimaa M, Erdine S, Brambilla G, Bombelli M, Dell'Oro R, Notari M, Mancia G. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. European Heart Journal. 32: 218-25. PMID 21047877 DOI: 10.1093/eurheartj/ehq394  0.305
2011 Farkas K, Fábián E, Kolossváry E, Járai Z, Farsang C. Noninvasive assessment of endothelial dysfunction in essential hypertension: Comparison of the forearm microvascular reactivity with flow-mediated dilatation of the brachial artery International Journal of Angiology. 12: 224-228. DOI: 10.1007/S00547-003-1000-8  0.569
2009 Farsang C, Naditch-Brule L, Avogaro A, Ostergren J, Verdecchia P, Maggioni A, van de Borne P, Lins R, Roca-Cusachs A. Where are we with the management of hypertension? From science to clinical practice. Journal of Clinical Hypertension (Greenwich, Conn.). 11: 66-73. PMID 19222670 DOI: 10.1111/J.1751-7176.2008.00066.X  0.376
2008 Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J. Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. Kidney International. Supplement. S60-3. PMID 19034329 DOI: 10.1038/Ki.2008.514  0.338
2008 Arnold C, Englert Z, Szabadhegyi C, Farsang C. [Digital risk analysis of cardiovascular diseases: new opportunities for the patients. Cardiovascular prevention program in the praxis]. Orvosi Hetilap. 149: 677-84. PMID 18387871 DOI: 10.1556/Oh.2008.28353  0.313
2008 Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Egido J. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. European Journal of Pharmacology. 586: 259-65. PMID 18374327 DOI: 10.1016/J.Ejphar.2008.02.042  0.367
2008 Arnold C, Englert Z, Szabadhegyi C, Farsang C. Digitalised Risk Analysis of Cardiovascular Diseases: New Possibility to Make Patients Motivated. Use of the Cardiovascular Prevention (CARMEN) Programme in the Practice Hungarian Medical Journal. 2: 407-416. DOI: 10.1556/Hmj.2.2008.28353  0.305
2007 Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Pressure. Supplement. 2: 19-24. PMID 18046975 DOI: 10.1080/08038020701561737  0.423
2007 Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Journal of Human Hypertension. 21: 780-7. PMID 17541390 DOI: 10.1038/sj.jhh.1002220  0.307
2007 Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. American Heart Journal. 153: 881-8. PMID 17452168 DOI: 10.1016/J.Ahj.2007.02.029  0.339
2007 Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hérnandez G, Egido J. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arteriosclerosis, Thrombosis, and Vascular Biology. 27: 168-74. PMID 17053166 DOI: 10.1161/01.Atv.0000250616.26308.D7  0.35
2006 Rosei EA, Salvetti M, Farsang C. European Society of Hypertension Scientific Newsletter: treatment of hypertensive urgencies and emergencies. Journal of Hypertension. 24: 2482-5. PMID 17082737 DOI: 10.1097/Hjh.0B013E328010B8F3  0.382
2005 Farkas K, Nemcsik J, Kolossváry E, Járai Z, Borvendég J, Nádory E, Farsang C, Kiss I. [Noninvasive assessment of endothelial function in hemodialyzed hypertensive patients by laser Doppler flowmetry]. Orvosi Hetilap. 146: 2589-94. PMID 16468613  0.61
2005 Kolossváry E, Kollár A, Pintér H, Erényi E, Kiséry I, Péter H, Farkas K, Mogán L, Farsang C, Kiss I. Bilateral axillobrachial and external carotid artery manifestation of giant cell arteritis: important role of color duplex ultrasonography in the diagnosis. International Angiology : a Journal of the International Union of Angiology. 24: 202-5. PMID 15997226  0.516
2005 Farkas K, Nemcsik J, Kolossváry E, Járai Z, Nádory E, Farsang C, Kiss I. Impairment of skin microvascular reactivity in hypertension and uraemia. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 20: 1821-7. PMID 15985514 DOI: 10.1093/Ndt/Gfh944  0.64
2005 Kiss I, Farsang C, Rodicio JL. Treatment of hypertension in dialysed patients. Journal of Hypertension. 23: 222-6. PMID 15643149 DOI: 10.1097/00004872-200501000-00038  0.397
2005 Szirmai LA, Arnold C, Farsang C. Improving control of hypertension by an integrated approach -- results of the 'Manage it well!' programme. Journal of Hypertension. 23: 203-11. PMID 15643143 DOI: 10.1097/00004872-200501000-00031  0.366
2004 Farkas K, Kolossváry E, Járai Z, Nemcsik J, Farsang C. Non-invasive assessment of microvascular endothelial function by laser Doppler flowmetry in patients with essential hypertension. Atherosclerosis. 173: 97-102. PMID 15177128 DOI: 10.1016/J.Atherosclerosis.2003.11.015  0.614
2004 Finta E, Alföldi S, László F, Nemcsik J, Kun E, Eröss A, Farsang C, Kiss I. EFFECT OF RILMENIDINE ON HEART RATE VARIABILITY AND BAROREFLEX SENSITIVITY IN HYPERTENSIVE PATIENTS Journal of Hypertension. 22: S206. DOI: 10.1097/00004872-200406002-00718  0.348
2004 Farkas K, Nemcsik J, Kolossváry E, Járai Z, Borvendég J, Farsang CS, Kiss I. SKIN MICROVASCULAR REACTIVITY IN HYPERTENSIVE PATIENTS WITH AND WITHOUT END STAGE RENAL DISEASE Journal of Hypertension. 22: S194. DOI: 10.1097/00004872-200406002-00672  0.562
2003 Kjeldsen SE, Erdine S, Farsang C, Sleight P, Mancia G. 1999 WHO/ISH Hypertension Guidelines--highlights & ESH Update. Blood Pressure. 12: 181-2. PMID 12875481 DOI: 10.1097/00004872-200112000-00026  0.383
2002 Farsang C, Sleight P. Isolated systolic hypertension: cardiovascular risk and treatment benefits. Journal of Hypertension. 19: 2279-81. PMID 11725174 DOI: 10.1097/00004872-200112000-00023  0.381
2001 Kjeldsen SE, Os I, Farsang C, Mallion JM, Hansson L, Sleight P. Treatment of hypertension in patients with type-2 diabetes mellitus. Journal of Hypertension. 18: 1345-6. PMID 10994767 DOI: 10.1097/00004872-200018090-00023  0.313
2000 Farsang C, Garcia-Puig J, Niegowska J, Baiz AQ, Vrijens F, Bortman G. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. Journal of Hypertension. 18: 795-801. PMID 10872566 DOI: 10.1097/00004872-200018060-00019  0.362
2000 Hansson L, Lithell H, Skoog I, Bánki CM, Breteler M, Castaigne A, Correia M, Degaute J, Elmfeldt D, Engedal K, Farsang C, Ferro J, Hachinski V, Hofman A, James OFW, et al. Study on COgnition and Prognosis in the Elderly (SCOPE): Baseline Characteristics Blood Pressure. 9: 146-151. DOI: 10.1080/080370500453483999  0.322
1999 Hansson L, Lithell H, Skoog I, Baro F, Bánki CM, Breteler M, Carbonin PU, Castaigne A, Correia M, Degaute JP, Elmfeldt D, Engedal K, Farsang C, Ferro J, Hachinski V, et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Pressure. 8: 177-83. PMID 10595696 DOI: 10.1080/080370599439715  0.347
1999 FARSANG C. Losartan treatment of patients with isolated systolic hypertension. American Journal of Hypertension. 12: 140. DOI: 10.1016/S0895-7061(99)80498-1  0.392
1991 Kiss I, Farsang C. Nifedipine-prazosin interaction in patients with essential hypertension. Cardiovascular Drugs and Therapy. 3: 413-5. PMID 2487537 DOI: 10.1007/Bf01858112  0.311
1990 Kiss I, Lázár A, Paulin F, Farsang C. Retrospective analysis of clinical data of normotensive and hypertensive pregnant women and their newborns. Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension. 7: S336-7. PMID 2632737 DOI: 10.1097/00004872-198900076-00164  0.337
1984 Farsang C, Varga K, Vajda L, Alföldi S, Kapocsi J. Effects of clonidine and guanfacine in essential hypertension. Clinical Pharmacology and Therapeutics. 36: 588-94. PMID 6386275 DOI: 10.1038/Clpt.1984.226  0.346
1980 Farsang C, Debreczeni L, Kerényi A, Takács L. Postocclusion hyperemia in the isolated fibrillating blood-perfused dog heart. Cardiology. 65: 65-84. PMID 7363285 DOI: 10.1159/000170797  0.341
1979 Farsang C, Debreczeni L, Kerényi A, Takács L. Effect of phenoxybenzamine and propranolol on myocardial reactive hyperaemia in fibrillating canine heart. Pflugers Archiv : European Journal of Physiology. 379: 223-8. PMID 223117 DOI: 10.1007/Bf00581425  0.301
Show low-probability matches.